Breast cancer causes and treatment: where are we going wrong?

被引:7
|
作者
Seymour, Colin B. [1 ]
Mothersill, Carmel [1 ]
机构
[1] McMaster Univ, Med Phys & Appl Radiat Sci Dept, Hamilton, ON L8S 2C1, Canada
来源
BREAST CANCER-TARGETS AND THERAPY | 2013年 / 5卷
关键词
breast cancer; causes; treatment; questioning paradigms;
D O I
10.2147/BCTT.S44399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This discussion paper seeks to provoke thoughts about cancer research in general, and why breast cancer in particular is not yet "curable". It asks the question - are we looking at the disease in the right way? Should we regard cancer as a progressive state, which is part of aging? Should we tailor treatment to "reset" the system or slow progression rather than try using toxic and aggressive therapy to kill every cancer cell (and sometimes also the patient)? The thesis is presented that we need to revisit our fundamental beliefs about the disease and then ask why we cling to beliefs that clearly are no longer valid. The paper also questions the role of ethics boards in hampering research and discusses the concept that breast cancer is an industry with vested interests involving profiteering by preventive, diagnostic, and therapeutic players. Finally, the paper suggests some ways forward based on emerging concepts in system biology and epigenetics.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 50 条
  • [41] Personalized medicine in oncology: where have we come from and where are we going?
    Andre, Fabrice
    Ciccolini, Joseph
    Spano, Jean-Philippe
    Penault-Llorca, Frederique
    Mounier, Nicolas
    Freyer, Gilles
    Blay, Jean-Yves
    Milano, Gerard
    PHARMACOGENOMICS, 2013, 14 (08) : 931 - 939
  • [42] Breast cancer screening: Where have we been and where are we going? A personal perspective based on history, data and experience (vol 50c, pg 91, 2018)
    Kopans, Daniel B.
    CLINICAL IMAGING, 2018, 50 : 91 - 91
  • [43] Personalised COPD care: Where are we going?
    Roche, N.
    Martin, C.
    Burgel, P. -R.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2018, 74 (05) : 315 - 326
  • [44] miRNA - Therapeutic tool in breast cancer? Where are we now?
    Zaleska, Karolina
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2015, 20 (02) : 79 - 86
  • [45] Molecular targeted therapies in breast cancer: Where are we now?
    Widakowich, Christian
    de Azambuja, Evandro
    Gil, Thierry
    Cardoso, Fatima
    Dinh, Phuong
    Awada, Ahmad
    Piccart-Gebhart, Martine
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (7-8) : 1375 - 1387
  • [46] Integrating PARP inhibitors into the management of breast cancer: where are we?
    Azim, Hamdy A.
    Kassem, Loay
    Azim, Hatem, Jr.
    CHINESE CLINICAL ONCOLOGY, 2021, 10 (05)
  • [47] Progression of endocrine therapies for breast cancer: where are we headed?
    Arnedos, Monica
    Smith, Ian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (11) : 1651 - 1664
  • [48] Cow's Milk Allergy: Where have we Come from and where are we Going?
    Host, Arne
    Halken, Susanne
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2014, 14 (01) : 2 - 8
  • [49] Current and emerging therapies in premature ejaculation: Where we are coming from, where we are going
    Martin, Christopher
    Nolen, Hunter
    Podolnick, Jason
    Wang, Run
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (01) : 40 - 50
  • [50] Adjuvant chemotherapy in elderly patients with breast cancer: where are we?
    Wildiers, H
    Brain, EGC
    CURRENT OPINION IN ONCOLOGY, 2005, 17 (06) : 566 - 572